Omnipod 5 System Compared to Pump Therapy

NCT ID: NCT05409131

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 196 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-07
• Study Completion Date: 2025-01-10

Brief Summary

Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or continue to use their personal insulin pump with the study provided continuous glucose monitoring system.

Participants in France will be offered an optional extension of 12 months of Omnipod 5 System use.

Detailed Description

This is an outpatient study that consists of two phases, Phase 1 and Phase 2. There will be approximately 8 study visits conducted in person or via telehealth.

Phase 1 is a 14-day period to collect baseline sensor and insulin data where subjects will manage their diabetes at home per their usual routine using the study continuous glucose monitoring system.

Phase 2 is a 90-day period where subjects will be randomized into one of two groups. One group will use the Omnipod 5 system and the other group will continue to use their personal insulin pump with the study continuous glucose monitoring system.

Following the 90-day outpatient phase, participants in France will be offered the option to transition to use the CE-marked commercial Omnipod 5 System for an additional 12 months with the French interface.

Conditions

Type 1 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention Arm

Omnipod 5 System with Dexcom G6 continuous glucose monitoring system

Group Type: ACTIVE_COMPARATOR

Omnipod 5 System

Intervention Type: DEVICE

Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.

Control Arm

Participant's current insulin pump with Dexcom G6 continuous glucose monitoring system

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Omnipod 5 System

Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age at time of consent 18-70 years of age

2. Diagnosed with type 1 diabetes for at least 1 year. Diagnosis is based on investigator's clinical judgment.

3. On pump therapy for ≥ 3 months prior to screening and familiar with pump therapy concepts such as basal and bolus insulin delivery, and carbohydrate counting. Participants using automated insulin delivery (AID) devices, including devices with predictive low glucose suspend (PLGS), in the 3 months prior to screening, will be excluded from participating.

4. A1C 7.0-11.0% by point-of-care taken at screening visit

5. Willing to use and obtain U-100 insulin: (either insulin aspart (Novolog, NovoRapid), or insulin lispro (Humalog, Admelog)), as the primary insulin treatment

6. Must have a smartphone that supports the Dexcom app download and participants must be willing to use the app throughout the study

7. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol

8. Willing to wear the system continuously throughout the study

9. Willing and able to sign the Informed Consent Form (ICF)

Exclusion Criteria

1. Any medical condition, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal failure, eating disorders, or other conditions which in the opinion of the investigator, would put the participant at an unacceptable safety risk

2. History of severe hypoglycemia in the past 6 months

3. History of diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness or infusion set failure

4. Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1C.

5. Currently on systemic steroids or intends to receive systemic steroid treatment during study participation, including stable treatment for adrenal insufficiency. Inhaled, ophthalmic, topical, joint injection, and other locally applied steroids are allowed.

6. Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement

7. Use of non-insulin anti-hyperglycemic medication other than metformin, in the 12 weeks prior to the Baseline Visit. Participants taking metformin should remain on a steady dose during study participation.

8. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner)

9. Participation in another clinical study using an investigational drug or device within 30-days or 5 half-lives (whichever is longer) prior to screening, or intends to participate in any other study during this study period

10. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment

11. Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Insulet Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruth Weinstock, MD

Role: STUDY_CHAIR

State University of New York - Upstate Medical University

Eric Renard, Pr

Role: STUDY_CHAIR

Lapeyronie Montpellier University Hospital

Locations

Stanford University School of Medicine

Palo Alto, California, United States

Sansum Diabetes Research Institute

Santa Barbara, California, United States

University of Colorado Denver

Denver, Colorado, United States

Atlanta Diabetes

Atlanta, Georgia, United States

Northwestern University

Evanston, Illinois, United States

Joslin Diabetes Center

Boston, Massachusetts, United States

State University of New York, Upstate Medical University

Syracuse, New York, United States

Diabetes & Glandular Disease Clinic, P.A. (DGD Clinic)

San Antonio, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

University of Washington

Seattle, Washington, United States

Hopital Sud-Francilien

Corbeil-Essonnes, , France

Hospices Civils de Lyon - Centre du diabete Diab-eCare

Lyon, , France

CHRU de Montpellier, Hopital Lapeyronie - Departement d'endocrinologie, Diabete, Nutrition

Montpellier, , France

Hopital Lariboisiere - Centre Universitaire du Diabete et de ses Complications

Paris, , France

Countries

United States; France

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

OP5-003 (G6 CSII)

Identifier Type: -

Identifier Source: org_study_id